Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Integrates YUPELRI into Portfolio
· gurufocus.com
On September 28, 2026, Zymeworks Inc (NASDAQ: ZYME) finalized its acquisition of Theravance Biopharma, adding the respiratory drug YUPELRI (revefenacin) to its
On September 28, 2026, Zymeworks Inc (NASDAQ: ZYME) finalized its acquisition of Theravance Biopharma, adding the respiratory drug YUPELRI (revefenacin) to its ...